SITE010-0190

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-10-17

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-01 (study day 35); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 91); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-28 (study day 93); relationship: N

severe assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-02-16 (study day 112); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 200); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-09 (study day 286); relationship: not assessed

Data queries

No data queries.